Anxiety Disorders - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 273 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anxiety Disorders - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Anxiety Disorders - Pipeline Review, H2 2016', provides an overview of the Anxiety Disorders pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Anxiety Disorders Overview 11
Therapeutics Development 12
Pipeline Products for Anxiety Disorders - Overview 12
Pipeline Products for Anxiety Disorders - Comparative Analysis 13
Anxiety Disorders - Therapeutics under Development by Companies 14
Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 18
Anxiety Disorders - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Anxiety Disorders - Products under Development by Companies 23
Anxiety Disorders - Products under Investigation by Universities/Institutes 29
Anxiety Disorders - Companies Involved in Therapeutics Development 30
AbbVie Inc 30
Ache Laboratorios Farmaceuticos S/A 31
Adamed Sp. z o.o. 32
Addex Therapeutics Ltd 33
Amorsa Therapeutics Inc. 34
Avineuro Pharmaceuticals, Inc. 35
Azevan Pharmaceuticals, Inc. 36
Biohaven Pharmaceutical Holding Company Limited 37
Bionomics Limited 38
Boehringer Ingelheim GmbH 39
C4X Discovery Holdings PLC 40
Catalyst Pharmaceuticals, Inc. 41
Corcept Therapeutics Incorporated 42
Edgemont Pharmaceuticals, LLC 43
Eisai Co., Ltd. 44
Eli Lilly and Company 45
Fabre-Kramer Pharmaceuticals, Inc. 46
Gabather AB 47
GlaxoSmithKline Plc 48
GW Pharmaceuticals Plc 49
Humanetics Corporation 50
IntelGenx Corp. 51
Intra-Cellular Therapies, Inc. 52
INVENT Pharmaceuticals, Inc. 53
Lead Discovery Center GmbH 54
Marinus Pharmaceuticals, Inc. 55
Merz Pharma GmbH & Co. KgaA 56
Neuralstem, Inc. 57
Neurelis, Inc. 58
NeuroNascent, Inc. 59
Newron Pharmaceuticals S.p.A. 60
Nippon Chemiphar Co., Ltd. 61
Omeros Corporation 62
Otsuka Holdings Co., Ltd. 63
Pherin Pharmaceuticals, Inc. 64
Pragma Therapeutics 65
Protagenic Therapeutics Inc. 66
Suda Ltd 67
Sumitomo Dainippon Pharma Co., Ltd. 68
Synchroneuron Inc. 69
Tonix Pharmaceuticals Holding Corp. 70
Toray Industries, Inc. 71
Trevena, Inc. 72
TRImaran Pharma, Inc. 73
Turing Pharmaceuticals AG 74
Anxiety Disorders - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Target 76
Assessment by Mechanism of Action 81
Assessment by Route of Administration 85
Assessment by Molecule Type 87
Drug Profiles 89
18-MC - Drug Profile 89
acamprosate calcium SR - Drug Profile 90
ACH-36 - Drug Profile 92
ADN-2013 - Drug Profile 93
ADX-71441 - Drug Profile 94
ADX-71743 - Drug Profile 98
ADX-88178 - Drug Profile 99
alprazolam - Drug Profile 101
AM-3506 - Drug Profile 102
AVN-0189 - Drug Profile 103
AVN-101 - Drug Profile 104
AVN-628 - Drug Profile 105
BNC-210 - Drug Profile 106
brexpiprazole - Drug Profile 109
CPP-115 - Drug Profile 115
D-473 - Drug Profile 119
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 120
E-2508 - Drug Profile 121
evenamide - Drug Profile 122
FKW-00GA - Drug Profile 125
fluvoxamine maleate - Drug Profile 126
ganaxolone - Drug Profile 127
gepirone hydrochloride ER - Drug Profile 132
GT-001 - Drug Profile 134
HL-9001 - Drug Profile 135
HUF-101 - Drug Profile 136
IC-87201 - Drug Profile 137
INT-0036 - Drug Profile 138
INV-107 - Drug Profile 139
ITI-007 - Drug Profile 140
KDAC-0001 - Drug Profile 148
ketamine hydrochloride - Drug Profile 149
lorazepam - Drug Profile 150
lorazepam ER - Drug Profile 151
LSN-2535717 - Drug Profile 152
LY-2607540 - Drug Profile 153
midazolam hydrochloride - Drug Profile 154
modafinil - Drug Profile 155
nabiximols - Drug Profile 156
NC-2800 - Drug Profile 163
NEO-1940 - Drug Profile 164
NNI-351 - Drug Profile 165
NSI-189 - Drug Profile 166
OMS-527 - Drug Profile 170
Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 172
PGT-117 - Drug Profile 173
PH-94B - Drug Profile 174
PN-6047 - Drug Profile 176
PT-00114 - Drug Profile 177
remeglurant - Drug Profile 178
riluzole - Drug Profile 179
Rycal - Drug Profile 182
S-107 - Drug Profile 183
SCT-66 - Drug Profile 184
Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 185
Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain - Drug Profile 186
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile 187
Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile 188
Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile 189
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 190
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 191
Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 192
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 193
Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile 194
Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 195
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 196
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile 197
Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile 198
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 199
Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile 200
Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile 201
Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile 202
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 203
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 204
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 205
Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression - Drug Profile 206
Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile 207
Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile 208
Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile 209
SRX-246 - Drug Profile 210
SRX-251 - Drug Profile 212
STX - Drug Profile 214
Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile 215
TGFK-08AA - Drug Profile 216
TGSC-01AA(4) - Drug Profile 217
TNX-102 - Drug Profile 218
TRV-250 - Drug Profile 227
UCM-765 - Drug Profile 228
Vaccine for CNS Disorders - Drug Profile 229
VAD-1 - Drug Profile 230
VAD-2 - Drug Profile 231
VU-0431316 - Drug Profile 232
VU-0456810 - Drug Profile 233
ZL-006 - Drug Profile 234
Anxiety Disorders - Dormant Projects 235
Anxiety Disorders - Discontinued Products 250
Anxiety Disorders - Product Development Milestones 255
Featured News & Press Releases 255
Appendix 266
Methodology 266
Coverage 266
Secondary Research 266
Primary Research 266
Expert Panel Validation 266
Contact Us 266
Disclaimer 267

List of Tables

Number of Products under Development for Anxiety Disorders, H2 2016 18
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016 19
Number of Products under Development by Companies, H2 2016 20
Number of Products under Development by Companies, H2 2016 (Contd..1) 21
Number of Products under Development by Companies, H2 2016 (Contd..2) 22
Number of Products under Development by Companies, H2 2016 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2016 24
Comparative Analysis by Late Stage Development, H2 2016 25
Comparative Analysis by Clinical Stage Development, H2 2016 26
Comparative Analysis by Early Stage Development, H2 2016 27
Comparative Analysis by Unknown Stage Development, H2 2016 28
Products under Development by Companies, H2 2016 29
Products under Development by Companies, H2 2016 (Contd..1) 30
Products under Development by Companies, H2 2016 (Contd..2) 31
Products under Development by Companies, H2 2016 (Contd..3) 32
Products under Development by Companies, H2 2016 (Contd..4) 33
Products under Development by Companies, H2 2016 (Contd..5) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Anxiety Disorders - Pipeline by AbbVie Inc, H2 2016 36
Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 37
Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2016 38
Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2016 39
Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H2 2016 40
Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 41
Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016 42
Anxiety Disorders - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 43
Anxiety Disorders - Pipeline by Bionomics Limited, H2 2016 44
Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2016 45
Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H2 2016 46
Anxiety Disorders - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 47
Anxiety Disorders - Pipeline by Corcept Therapeutics Incorporated, H2 2016 48
Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2016 49
Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2016 50
Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2016 51
Anxiety Disorders - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016 52
Anxiety Disorders - Pipeline by Gabather AB, H2 2016 53
Anxiety Disorders - Pipeline by GlaxoSmithKline Plc, H2 2016 54
Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H2 2016 55
Anxiety Disorders - Pipeline by Humanetics Corporation, H2 2016 56
Anxiety Disorders - Pipeline by IntelGenx Corp., H2 2016 57
Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 58
Anxiety Disorders - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 59
Anxiety Disorders - Pipeline by Lead Discovery Center GmbH, H2 2016 60
Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 61
Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 62
Anxiety Disorders - Pipeline by Neuralstem, Inc., H2 2016 63
Anxiety Disorders - Pipeline by Neurelis, Inc., H2 2016 64
Anxiety Disorders - Pipeline by NeuroNascent, Inc., H2 2016 65
Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016 66
Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 67
Anxiety Disorders - Pipeline by Omeros Corporation, H2 2016 68
Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 69
Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016 70
Anxiety Disorders - Pipeline by Pragma Therapeutics, H2 2016 71
Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H2 2016 72
Anxiety Disorders - Pipeline by Suda Ltd, H2 2016 73
Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 74
Anxiety Disorders - Pipeline by Synchroneuron Inc., H2 2016 75
Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 76
Anxiety Disorders - Pipeline by Toray Industries, Inc., H2 2016 77
Anxiety Disorders - Pipeline by Trevena, Inc., H2 2016 78
Anxiety Disorders - Pipeline by TRImaran Pharma, Inc., H2 2016 79
Anxiety Disorders - Pipeline by Turing Pharmaceuticals AG , H2 2016 80
Assessment by Monotherapy Products, H2 2016 81
Number of Products by Stage and Target, H2 2016 83
Number of Products by Stage and Mechanism of Action, H2 2016 88
Number of Products by Stage and Route of Administration, H2 2016 92
Number of Products by Stage and Molecule Type, H2 2016 94
Anxiety Disorders - Dormant Projects, H2 2016 241
Anxiety Disorders - Dormant Projects (Contd..1), H2 2016 242
Anxiety Disorders - Dormant Projects (Contd..2), H2 2016 243
Anxiety Disorders - Dormant Projects (Contd..3), H2 2016 244
Anxiety Disorders - Dormant Projects (Contd..4), H2 2016 245
Anxiety Disorders - Dormant Projects (Contd..5), H2 2016 246
Anxiety Disorders - Dormant Projects (Contd..6), H2 2016 247
Anxiety Disorders - Dormant Projects (Contd..7), H2 2016 248
Anxiety Disorders - Dormant Projects (Contd..8), H2 2016 249
Anxiety Disorders - Dormant Projects (Contd..9), H2 2016 250
Anxiety Disorders - Dormant Projects (Contd..10), H2 2016 251
Anxiety Disorders - Dormant Projects (Contd..11), H2 2016 252
Anxiety Disorders - Dormant Projects (Contd..12), H2 2016 253
Anxiety Disorders - Dormant Projects (Contd..13), H2 2016 254
Anxiety Disorders - Dormant Projects (Contd..14), H2 2016 255
Anxiety Disorders - Discontinued Products, H2 2016 256
Anxiety Disorders - Discontinued Products (Contd..1), H2 2016 257
Anxiety Disorders - Discontinued Products (Contd..2), H2 2016 258
Anxiety Disorders - Discontinued Products (Contd..3), H2 2016 259
Anxiety Disorders - Discontinued Products (Contd..4), H2 2016 260